MCA
VRTX icon

Midwest Capital Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Midwest Capital Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$45.1K Hold
101
– – 0.02% 99
2025
Q4 		$45.8K Hold
101
– – 0.02% 91
2025
Q3 		$39.6K Hold
101
– – 0.02% 95
2025
Q2 		$45K Hold
101
– – 0.02% 90
2025
Q1 		$49K Hold
101
– – 0.03% 86
2024
Q4 		$40.7K Buy
+101
New +$46.8K 0.03% 97

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Midwest Capital Advisors's VRTX Position: Q1 2026 in Review

Midwest Capital Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q1 2026 at 101 shares worth $45.1K. The position accounts for 0.02% of the portfolio, ranked #99.

Midwest Capital Advisors first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $49K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Midwest Capital Advisors held 101 shares of Vertex Pharmaceuticals worth $45.1K as of Q1 2026.
  • Midwest Capital Advisors left its Vertex Pharmaceuticals share count unchanged in Q1 2026.
  • Vertex Pharmaceuticals made up 0.02% of Midwest Capital Advisors's portfolio in Q1 2026, its #99 holding.
  • Midwest Capital Advisors first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • Midwest Capital Advisors's Vertex Pharmaceuticals position peaked at $49K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Midwest Capital Advisors's 13F filing for Q1 2026, filed 24 Apr 2026.